secwatch.observer — SEC 8-K summary
======================================

Issuer:     Maze Therapeutics, Inc. (MAZE)
CIK:        0001842295
Form:       8-K
Filed at:   2026-05-12T20:07:51+00:00
Accession:  0001193125-26-219398
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maze Q1 net loss $24.2M; MZE829 reduces proteinuria 35.6% in Phase 2 AMKD trial
-------------------------------------------------------------------------------

- MZE829 Phase 2 HORIZON: 35.6% mean uACR reduction at week 12 in broad AMKD; 50% of patients had >30% reduction; no serious AEs.
- In severe FSGS subgroup, MZE829 achieved 61.8% mean uACR reduction; in non-diabetic AMKD, 48.6% reduction.
- Cash $362.9M at March 31, 2026; April 2026 raised ~$150M in offering plus $20M milestone from Shionogi; runway into 2029.
- Net loss $24.2M ($0.45/share) vs $32.8M ($1.15) YoY; license revenue $20M; R&D $34.1M, G&A $12.4M.
- MZE782 Phase 2 in PKU to start mid-2026 with topline data in 2027; Phase 2 in CKD expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/0001193125-26-219398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842295/000119312526219398/maze-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer